Home / Stocks / Morepen Lab. Ltd
MOREPENLAB

Morepen Lab. Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹90.77

Change

-1.6 (-1.73%)

Open

₹91.85

Prev. Close

₹92.37

Day High

₹92.0

Day Low

₹90.0

Volume Analysis

Traded

1,523,844

Delivered

5,054,104

Delivery %

37.43%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (5.33%)
  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (31.6%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹93.84 ₹92.92 ₹91.84 ₹90.92 ₹89.84 ₹88.92 ₹87.84
Fibonacci ₹92.92 ₹92.16 ₹91.68 ₹90.92 ₹90.16 ₹89.68 ₹88.92
Camarilla ₹91.32 ₹91.14 ₹90.95 ₹90.92 ₹90.59 ₹90.4 ₹90.22

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+120.8%

1 Week

-4.35%

1 Month

-21.36%

3 Months

-5.46%

6 Months

+111.54%

1 Year

+102.48%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹31.32

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

10.71%

Net margin 8.22% × asset turnover 0.78x × equity multiplier 1.67x

Company Overview

Sector

Healthcare

Market Cap

₹5,061 Cr

P/E (TTM)

26.8

ROE

5.33%

Book Value

₹25.2

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Morepen Lab. Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 51/100. The strongest factor is Financial Strength (100/100), while Cash Flow (12/100) is the weakest area to weigh before deciding. Notably: Low return on equity (5.33%); promoter holding is falling. Strong 3-year EPS growth (31.6%).

TopFund Score — Fundamentals Quality

51/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

46

Valuation

48

Cash Flow

12

Corporate Governance

56

Momentum

50

Institutional Ownership

34

Business Quality

48

Risk & Volatility

52

Liquidity

51

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 3.66 times its book value
  • −The company has delivered a poor sales growth of 8.73% over past five years.
  • −Company has a low return on equity of 9.26% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

INFOMERICS upgraded Morepen Laboratories' bank facilities rating to IVR A/Stable on 13 November 2026.

Morepen launches Desloratadine Rx generics in the U.S. and files first ANDA for Sitagliptin.

Nishant Jayesh Doshi resigns as Vice President, Corporate Finance & Investor Relations, effective 31 October 2026.

Newspaper Publication financial results for the quarter and half year ended 30 September 2026 and special window for transfer and dematerialization of physical shares

Morepen Laboratories promoted Charanjeet Chitakara and Vivan Prashar as of 27 Oct 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 422 445 423 455 438 453 466 425 412 484 485 570 746
Expenses + 388 394 375 404 394 417 424 401 381 438 460 488 623
Operating Profit 34 51 48 52 44 36 42 24 31 46 24 83 123
OPM % 8.0% 11.0% 11.0% 11.0% 10.0% 8.0% 9.0% 6.0% 7.0% 10.0% 5.0% 14.0% 16.0%
Other Income + 3 4 4 3 5 5 5 4 30 4 8 5 9
Interest 0 2 1 1 1 1 5 4 4 4 4 5 5
Depreciation 8 8 10 6 2 5 16 9 11 10 6 8 10
Profit before tax 29 44 42 48 46 35 26 16 46 35 23 75 117
Tax % 26.0% 27.0% 32.0% 25.0% 24.0% 24.0% 21.0% 26.0% 10.0% 22.0% 33.0% 24.0% 24.0%
Net Profit + 21 32 29 36 35 27 20 11 41 28 16 56 89
EPS in Rs 0 1 1 1 1 0 0 0 1 1 0 1 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 5 28 16 14 4 2 10 -7 -6 7 4 34 81

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 401 485 595 607 769 853 1,188 1,547 1,418 1,690 1,812 1,806 2,286
Expenses + 352 424 534 542 701 785 1,070 1,410 1,338 1,532 1,638 1,680 2,009
Operating Profit 48 62 61 65 68 69 119 137 80 159 174 126 276
OPM % 12.0% 13.0% 10.0% 11.0% 9.0% 8.0% 10.0% 9.0% 6.0% 9.0% 10.0% 7.0% 12.0%
Other Income + 1 -3 4 4 4 9 12 10 6 14 18 47 26
Interest 9 10 8 4 2 2 2 -7 2 4 8 16 18
Depreciation 39 35 34 34 40 37 30 28 28 33 29 36 35
Profit before tax 2 13 24 30 29 39 99 127 56 135 155 120 250
Tax % 6.0% -1.0% 0.0% 0.0% 1.0% 14.0% 1.0% 20.0% 31.0% 29.0% 24.0% 20.0% —
Net Profit + 2 13 24 30 29 34 97 102 39 97 118 96 188
EPS in Rs 0 0 1 1 1 1 2 2 1 2 2 2 3
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 9.0% 12.0% —
Sales growth 9 21 23 2 27 11 39 30 -8 19 7 0 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 78 91 106 136 163 194 335 483 651 745 1,047 1,137 1,272
Borrowings + 201 187 169 134 132 133 17 19 25 29 105 208 323
Other Liabilities + 121 156 173 226 230 246 416 473 332 417 517 482 602
Total Liabilities 489 524 538 586 615 663 858 1,070 1,110 1,293 1,778 1,936 2,306
Fixed Assets + 322 297 272 264 236 216 225 252 267 307 489 513 583
CWIP 0 0 0 0 0 0 2 14 17 24 28 22 23
Investments 0 0 0 0 0 1 1 0 0 1 85 124 118
Other Assets + 167 227 266 321 379 446 631 804 827 960 1,176 1,277 1,582
Total Assets 489 524 538 586 615 663 858 1,070 1,110 1,293 1,778 1,936 2,306
Equity Capital 90 90 90 90 90 90 90 96 102 102 110 110 110

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 51 50 41 63 17 11 51 -60 -91 73 32 33
Cash from Investing Activity + -32 -27 -14 -27 -13 -12 -70 -32 -47 -83 -322 -126
Cash from Financing Activity + -19 -27 -24 -38 0 5 47 66 144 5 300 97
Net Cash Flow 0 -4 3 -1 4 4 28 -26 6 -5 10 4
Free Cash Flow 46 41 31 37 6 -6 10 -127 -137 -8 -182 -127
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 105 81 66 98 26 25 44 -26 -94 70 40 46

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 38.22% → 35.66%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 57.46% 57.76% 57.96% 60.57% 60.46% 60.72% 61.09% 61.22% 61.46% 61.5% 61.59% 59.19%
Promoters 38.22% 38.22% 38.22% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66%
Government 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
FII 2.11% 1.85% 1.67% 2.08% 2.22% 1.94% 1.72% 1.62% 1.62% 1.59% 1.46% 3.43%
DII 2.21% 2.15% 2.14% 1.69% 1.64% 1.67% 1.5% 1.49% 1.25% 1.25% 1.28% 1.7%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Morepen Lab. Ltd (this stock) 5,061 26.8 3.67 5.33%
Orchid Pharma Limited 5,296 293.0 2.95 1.49%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%
Senores Pharmaceuticals L 5,409 40.5 5.39 13.4%
Artemis Med Service Ltd 5,415 46.2 5.47 12.0%
Sahajanand Medical Tech L 5,427 75.6 — 10.4%
Gujarat Themis Biosyn Ltd 4,659 239.0 4.55 16.2%

Which Mutual Funds Hold Morepen Lab. Ltd?

Frequently Asked Questions about Morepen Lab. Ltd

Community Sentiment

What are other investors saying about Morepen Lab. Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.